TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with congenital hyperinsulinism~Exclusion Criteria:~* Acute medical illness~* History of other systemic chronic disease such as cardiac failure, renal insufficiency, hepatic insufficiency, chronic obstructive pulmonary disease, anemia, or uncontrolled hypertension~* Pregnancy~* Diabetes mellitus~* Use of medications that affect glucose metabolism, such as glucocorticoids, beta agonists, diazoxide and octreotide.~* Subjects will be eligible to participate 48 hrs after the last dose of octreotide and 72 hrs after last dose of diazoxide

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Exendin-(9-39) first, the Vehicle (Type: EXPERIMENTAL): Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
- Vehicle first, then Exendin-(9-39) (Type: PLACEBO_COMPARATOR): Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physical Therapy for Functional Constipation in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children diagnosed as functional constipation.~* aged from 4 to 18 years old~* from both sex~Exclusion Criteria:~* children diagnosed as constipation caused by medicine Bowel surgery, Endocrine and metabolic disorders , Neurological and psychiatric disorders.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Control group (A) (Type: EXPERIMENTAL): conventional treatment by diet regimen and laxatives
- study Group (B) (Type: EXPERIMENTAL): physical therapy program in addition to conventional treatment by diet regimen and laxatives

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ETEC Logistics Trial (TREK)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult men and women 18-64 years of age inclusive at screening~* Signed Informed Consent form~* Planned travel to an area within 2 ½ hours traveling distance of Cuernavaca or Guadalajara, Mexico or Antigua, Guatemala (minimum stay of 7 days)~* If female who is not post-menopausal or surgically sterile, negative pregnancy test (within 24 hours prior to vaccination) and agreement to employ an effective form of birth control or practice abstinence through the end of the study.~Exclusion Criteria:~* Clinically significant abnormalities as determined by the Investigator/clinician during physical inspection~* Received investigational product from 30 days before date of first vaccination or during the entire study period~* Ever received LT, ETEC, or cholera vaccine~* History of traveler's diarrhea within the previous year~* Travel to a developing country within the last year~* Women who are pregnant or breastfeeding~* History of achlorhydria~* Evidence of immunosuppression, including concomitant immunosuppressive therapy; fever \> 99.5°F (37.5°C) on day of vaccination~* Current problems with alcohol or substance abuse~* An employee of the study clinic~* Sensitivity or allergy to any of the vaccine components~* History of significant blood loss, blood product donation, or blood product recipient in the previous 60 days~* Planned use of Imodium or antibiotics for self treatment of diarrhea during the study period~* Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; and~* Medical history of acute or chronic GI illness or major GI surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
- Group 2 (Type: PLACEBO_COMPARATOR): Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exercise Intervention on Aging-related Motor Decline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Living persons between 60 and 85 years of age~Exclusion Criteria:~* unmanaged diabetes~* participants completing vigorous exercise per week~* participants whose profession requires vigorous physical labor~* contraindication to magnetic resonance imaging

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Stretching Exercise Intervention (Type: EXPERIMENTAL): A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
- Aerobic Exercise Intervention (Type: EXPERIMENTAL): B. Interval aerobic cycling under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted between 50-85% of age-related maximum.
- Self Monitoring Intervention (Type: EXPERIMENTAL): C. 6 month self-monitored training phase during which time participants will exercise using a take home bike ergometer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Curriculum Evaluation of a Novel Health and Wellness Program Within New York City Schools

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Male or female students attending NYC schools~Exclusion Criteria:~* Lack of permission to attend physical education class

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Health and Wellness program (Type: EXPERIMENTAL): Behavioral intervention
- Physical Education Class (Type: ACTIVE_COMPARATOR): Behavioral intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Cardioprotective Effect of Sevoflurane

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* the degree I or II of Cardiac Anesthesia Risk Evaluation score~* angiographically verified coronary artery disease~* left ventricular ejection fraction higher than 40%~Exclusion Criteria:~* atrioventricular conduction disturbances~* previously ventricular arrhythmias requiring antiarrhythmic treatment~* atrial fibrillation with rapid ventricular response~* myocardial infarction or stroke within 6 months~* diabetes mellitus~* end-stage of obstructive or restrictive pulmonary disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact Insole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hallux valgus with angle of at least 20°,~* single or bilateral hallux valgus.~Exclusion Criteria:~* history of foot operations,~* rheumatoid arthritis and gouty arthritis.~* Any contraindication on BTA administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- botulinum toxin type A. HV angle (Type: ACTIVE_COMPARATOR): intramuscular injection of BTA into target muscle
- Normal saline, HV angle (Type: PLACEBO_COMPARATOR): intramuscular injection of normal saline into target muscle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Breast adenocarcinoma treated by neoadjuvant or adjuvant chemotherapy within 12 months prior to study enrollment~* WHO performance status 0-1~* Age ≥18 years old~* Affiliation to a social security regime or beneficiary of equivalent social protection~* Written informed consent provided before any study specific procedures~Complementary inclusion criterion for randomization~- Proved vitamin D deficiency as defined by serum vitamin D level lower than 30 ng/ml (75 nmol/L).~Exclusion Criteria:~* Metastatic disease~* History or presence of any other malignancy (except curatively treated nonmelanoma skin cancer or in situ cervix carcinoma) .............~traités dans les 5 ans précédents.~* Contraindication to calcium or cholecalciferol~* Known severe hypersensitivity to vitamin D or to calcium supplementation or to one of the excipients.~* Disease and/or medical conditions accompanied by hypercalcaemia and/or hypercalciuria~* Calcium lithiasis and tissue calcification~* Hypervitaminosis D~* Presence of significant comorbidities:~  i) Uncontrolled endocrine disease ii) Known disorders of calcium phophorus laboratory testing iii) Proved osteopenia or osteoporosis requiring vitamin D and calcium supplements~* Concomitant treatment with other experimental products or another vitamin D calcium treatment~* Pregnancy, breastfeeding or of reproductive potential not using an effective contraceptive method~* Legal inability or restricted legal ability. Medical or psychological conditions not allowing proper study completion or informed consent signature

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional vitamin D and calcium supplementation (Type: ACTIVE_COMPARATOR): Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
- vitamin D supplementation tailored to vitamin D deficiency (Type: EXPERIMENTAL): Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level \< 30 ng/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Medical history of chronic migraine for at least 6 months~* 15 or more headache days during a 4 week period~Exclusion Criteria:~* Previous use of any botulinum toxin of any serotype for any reason~* Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis~* Treatment of headache using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction, dental splints, or injection of anesthetics/steroids within 4 weeks prior to the week -4 screening visit~* Use of any headache prophylaxis medication within 4 weeks prior to the week -4 screening visit

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum toxin type A Dose 1 (Type: EXPERIMENTAL): Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
- Botulinum toxin type A Dose 2 (Type: EXPERIMENTAL): Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Placebo (Normal Saline) intramuscular injections into specified muscles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (age 18-75) with chronic HBV (positive for serum hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months) prior to baseline~* Anti-HBV treatment-naive adults; adults who have taken oral anti-HBV nucleoside therapy with the last dose ≥ 24 weeks prior to screening are also eligible.~* Positive or negative for hepatitis B e antigen (HBeAg)~* HBV DNA ≥ 20,000 IU/ml (HBeAg-positive participants) and ≥ 2,000 IU/ml (HBeAg-negative participants)~* Alanine aminotransferase (ALT) \> 54 U/L and ≤ 400 U/L for men and \> 36 U/L and ≤ 300 U/L for women~* Creatinine clearance ≥ 70 mL/min~* Negative serum pregnancy test for females of childbearing potential~* Sexually active females of childbearing potential must agree to use a protocol-recommended method of contraception throughout the study and for 30 days following the last dose of study medication~* Lactating females must agree to discontinue nursing before initiation of study investigational medicinal product~Exclusion Criteria:~* Known bridging fibrosis or cirrhosis and/or decompensated liver disease~* Evidence of hepatocellular carcinoma~* Significant kidney, heart, lung, neurological, autoimmune disease, or bone disease (eg, osteomalacia,chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis, multiple bone fractures)~* Absolute neutrophil count \< 1,500/mm\^3, platelet \< 100,000/mm\^3, hemoglobin \< 10 g/dL (female) or \< 11 g/dL (male)~* History of severe depression or severe psychiatric disease~* Thyroid dysfunction~* Coinfection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TDF+Peg-IFN 48 Weeks (Type: EXPERIMENTAL): TDF plus Peg-IFN for 48 weeks
- TDF 48 Weeks + Peg-IFN 16 Weeks (Type: EXPERIMENTAL): TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
- TDF 120 Weeks (Type: ACTIVE_COMPARATOR): TDF monotherapy for 120 weeks
- Peg-IFN 48 Weeks (Type: ACTIVE_COMPARATOR): Peg-IFN monotherapy for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin for Alcohol Relapse Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets criteria for alcohol use disorder based on DSM-5 criteria~2. Meets criteria for history of alcohol withdrawal based on DSM-5 criteria~3. Able to maintain abstinence for a minimum of 3 days prior to randomization as verified by self report, urine ETG, and breathalyzer.~Exclusion Criteria:~1. Significant psychiatric or medical illness~2. No other substance abuse~3. Taking other medications known to treat alcohol use disorder~4. Unstable living arrangements~5. Significant legal problems pending

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin (Type: EXPERIMENTAL): Gabapentin up to 1200 mg per day in 3 divided doses
- placebo (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Study About Human Adipose-Derived Stem Cells in the Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* stroke investigators with age 65 to 80 years~* history of stroke between six months and 10 years~* Systolic pressure and Diastolic pressure were maintained under 160 mmHg and 110 mmHg~* INR \< 2.5, platelets counts 1-5 x 10\^5/μl~* Damaged area range between 0.5 cm to 6 cm by brain MRI~Exclusion Criteria:~* Pregnant women~* Investigators with AIDS, cancer, liver dysfunction~* Others can't fit into the trial evaluate by investigator

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GXNPC1 (Type: EXPERIMENTAL): Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female subjects, 6-12 years of age, inclusive, with a diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM IV), confirmed with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).~2. ADHD-RS-IV-Parent Version: Investigator Administered and Scored score of at least 26.~3. CGI-S score of at least 4~4. Weight of at least 20 kg.~5. Free of medication for the treatment of ADHD or any psychosis for at least one week prior to enrollment.~Exclusion Criteria:~1. Current or lifetime diagnosis of major depressive disorder, bipolar disorder, personality disorder, Tourette's disorder, or psychosis not otherwise specified.~2. Currently meeting DSM-IV criteria for pervasive developmental disorder, obsessive compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as primary diagnosis.~3. Significant systemic disease.~4. Evidence of suicidality within the six months before Screening or at Screening.~5. BMI greater than 95th percentile for the appropriate age and gender.~6. Pregnancy or refusal to practice abstinence during the study for female subjects of childbearing potential (FOCP).~7. Substance or alcohol use during the last three months.~8. Positive urine screen for cotinine, alcohol, or drugs of abuse at Screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, qd, oral capsule
- 100mg SPN-812 (Type: EXPERIMENTAL): 100mg SPN-812, qd, oral capsule
- 200mg SPN-812 (Type: EXPERIMENTAL): 200mg SPN-812, qd, oral capsule
- 300mg SPN-812 (Type: EXPERIMENTAL): 300mg SPN-812, qd, oral capsule
- 400mg SPN-812 (Type: EXPERIMENTAL): 400mg SPN-812, qd, oral capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete